Last updated: July 7, 2026
Executive summary: Horizon Pharma AG sued Watson Laboratories, Inc. in the U.S. District Court for the Southern District of Florida over alleged patent infringement in connection with Watson’s Abbreviated New Drug Application (ANDA) for a Horizon product. The matter is docketed as Florida | 0:13-cv-61868. A litigation summary and infringement/exclusivity analysis cannot be produced from the case identifier alone because the complaint claims asserted patents, the Orange Book/drug reference product, the asserted claims, the FDA submission details, and the litigation procedural posture are not specified.
H1: Horizon Pharma AG v. Watson Laboratories Inc. Florida 0:13-cv-61868: Litigation Summary, Patent Estate, and Generic Launch Risk
What patents were asserted in Horizon Pharma AG v. Watson Laboratories, Inc. (0:13-cv-61868)?
A complete patent infringement and estate analysis requires the asserted patent numbers and claim mapping (the patents listed in the complaint and any amended pleadings). The case number “0:13-cv-61868” by itself does not identify:
- the drug (active ingredient and dosage form) tied to the ANDA,
- the asserted Orange Book patents,
- the specific claims alleged to be infringed,
- any method-of-use versus formulation versus composition-of-matter categories.
Which Horizon drug and Orange Book listed patents were at issue in 0:13-cv-61868?
A Horizon v. Watson ANDA infringement case is usually driven by Orange Book listings. Without the referenced FDA NDA/Orange Book entry, the analysis cannot determine:
- the reference listed drug (RLD),
- the listed patents (composition, method of use, formulations, polymorphs, process),
- whether the patents were tied to exclusivity periods (NCE, orphan drug, pediatric exclusivity, 505(b)(2) provisions),
- whether the lawsuit targeted “early” market entry or post-approval non-infringement.
What was Watson’s ANDA paragraph (IV), and when did FDA approve or tentatively approve it?
ANDA paragraph certifications (Paragraph IV versus I, II, III) determine the launch timing risk and the legal triggers for filing deadlines (30-month stay, court stay eligibility, and settlement timing). The case identifier does not provide:
- the certification(s) to the asserted patents,
- the associated NDA number and Orange Book patents,
- any FDA approval dates or tentative approval dates,
- whether Watson entered at risk following patent expiry or after a settlement.
When does FDA exclusivity or patent exclusivity for the Horizon product expire relative to the lawsuit timeline?
Exclusivity and patent timelines require:
- exact patent expiration dates (including PTA and any pediatric extension),
- any exclusivity blocks (5-year NCE, 7-year orphan, 3-year new clinical investigation),
- listed pediatric exclusivity extensions,
- whether the asserted patents include expiring sooner “trigger” patents.
Those dates are not derivable from the docket number alone.
How did the court rule in Horizon Pharma AG v. Watson Laboratories (S.D. Fla.)?
A true litigation summary must reference the procedural outcomes:
- motion to dismiss or venue/standing rulings,
- claim construction orders,
- summary judgment decisions,
- preliminary injunction rulings,
- final judgment and whether infringement was found.
The case identifier alone does not supply orders, docket events, or final disposition.
Were there settlement agreements, consent judgments, or stipulated dismissal terms?
Settlement analysis requires the settlement document or docket entries specifying:
- whether a covenant-not-to-sue or a license was granted,
- the stated “entry date” and any agreed design-around,
- the scope of patents released,
- whether the parties stipulated to dismissal with or without prejudice,
- any ongoing litigation or cross-claims.
Those elements are not included in the case number.
What generic entry risks existed for Watson based on the asserted claim scope?
Entry risk depends on:
- whether the asserted claims cover core active drug composition, dosage/formulation, or specific use indications,
- whether Watson’s product design avoided claim elements,
- whether invalidity defenses were likely under the asserted patent art,
- whether design-around strategies were constrained by manufacturing/process claims.
The necessary claim scope information is not available in the provided prompt.
How many patents cover the relevant Horizon product, and what is the strength of the patent estate?
A patent estate strength assessment needs:
- the full set of Orange Book patents tied to the RLD,
- prosecution history signals (continuations, claim breadth, terminal disclaimers),
- litigation history (prior PTAB challenges, IPR outcomes, district court invalidity rulings),
- geographic coverage where relevant (US patents only, but also whether foreign counterparts exist).
This cannot be computed without the drug and listed patents.
What patent litigation affects the same drug class or same Horizon active ingredient?
Comparable-drug and class-wide litigation requires identifying:
- the specific active ingredient and reference product,
- other defendants in related ANDA suits,
- the shared asserted patents and whether outcomes converged.
Without drug identification, no comparative landscape can be built.
Key Takeaways
- A litigation summary and patent/exclusivity analysis for Horizon Pharma AG v. Watson Laboratories, Inc., Florida | 0:13-cv-61868 cannot be completed from the docket identifier alone because the prompt does not specify the asserted patents, referenced drug/Orange Book entry, ANDA certification details, or the case outcomes required for infringement, invalidity, exclusivity, and entry-risk analysis.
FAQs
- What court docket entries typically confirm an ANDA Paragraph IV suit in S.D. Fla.?
- How do 30-month stays interact with patent expiry for ANDA litigation?
- What makes method-of-use patent claims harder to design around than formulation claims?
- How do consent judgments usually set market-entry dates in Horizon-style ANDA settlements?
- What Orange Book data points are needed to build a complete patent-expiration timeline?
References
- (No citable sources provided in the prompt.)
